For Irish life sciences founders expanding into the U.S., regulatory divergence is a strategic opportunity. Companies that align regulatory planning with corporate and investment objectives can use differences to drive growth and strengthen market credibility.

By Michael E. Burke

Irish life sciences founders expanding into the United States face a regulatory environment that differs from the European Union in substance, legal culture, and market expectations. The opportunity can be substantial, particularly for companies that plan carefully around regulatory approvals and related execution risks.

In this sector, those questions are rarely peripheral; they often shape valuation, deal timing, and the credibility of the business itself. Regulatory divergence, however, should not be seen only as an obstacle. Used thoughtfully, it can also create strategic opportunities.

A central challenge is that the EU and U.S. regulate medicines and medical devices through different institutional models. Although both systems are designed to protect safety and efficacy, they can diverge in evidentiary expectations, submission pathways, and post-market obligations.

For Irish companies accustomed to EU and HPRA processes, entry into the U.S. market often requires earlier, more deliberate decisions on trial design, product sequencing, and regulatory engagement-for example, adjusting endpoints, real-world evidence plans, or safety follow-up to meet FDA expectations, and deciding sooner whether to pursue a U.S.-first, EU-first, or parallel pathway.

The U.S. system also rewards early, structured interaction through mechanisms such as pre-IND and similar meetings, so teams may need to build sustained regulatory dialogue-and the internal resources to support it-into the business plan at a much earlier stage.

Irish life sciences companies can turn this divergence into an advantage by using sequencing strategically. For some Class II devices, a CE-first strategy allows earlier commercialization in Europe, generation of real-world performance data, and refinement of health-economic evidence before tackling a 510(k) or De Novo submission in the United States.

For more innovative technologies facing tighter EU timelines, securing FDA clearance first can create momentum and credibility that later supports MDR certification and European market access.

There is also room for disciplined arbitrage in how products are classified and routed through each system's approval pathways. Where a legitimate predicate exists, a company can structure indications and technical characteristics to qualify for the U.S. 510(k) route, avoiding the greater time and evidentiary burden of De Novo or PMA, while still placing the same device into an appropriate, but not unnecessarily onerous, risk class and conformity route under MDR.

The objective is not to downplay risk, but to avoid locking a product into the most demanding category in both jurisdictions simply because of differences in regulatory architecture.

Differences in evidence expectations can be used constructively if they are built into the development plan from the outset. A manufacturer might treat an initial European launch as a platform for robust post-market clinical follow-up, generating high-quality real-world data that later strengthens a U.S. submission or label expansion.

Equally, a focused U.S. launch under a clear real-world evidence framework can produce data that support EU renewals, variations, or pricing discussions. In both directions, the company is using divergent post-market rules to build the right evidence in the most efficient setting.

Group structure can likewise reflect the strengths of each regulatory and industrial environment. Many Irish life sciences businesses centralize design control, manufacturing, and quality systems in Ireland, while using a U.S. subsidiary as the formal "manufacturer" for American purposes.

That U.S. entity manages establishment registration, device listing, labeling, and day-to-day agency interaction, while the Irish base anchors global quality and supply. This division of roles lets the business meet both MDR and FDA expectations, but with functions located where the regulatory and operational context is most supportive.

For Irish life sciences founders, the broader lesson is that U.S. expansion should be treated as a coordinated transatlantic strategy rather than a simple commercial extension. The most resilient businesses align regulatory planning, corporate structure, tax, governance, talent strategy, and compliance from the outset.

Done well, that approach does more than reduce legal risk; it can improve investor confidence, preserve agility, and help companies use transatlantic differences to their advantage while remaining credible with regulators, counterparties, and the market.